Sionna Therapeutics Reports Q3 2026 Financial Results; Net Loss of $32.4M
Sionna Therapeutics reported a Q3 2026 net loss of $32.4 million, or $(0.72) per share, compared to a net loss of $20.3 million, or $(0.46) per share, in Q3 2025. Research and development expenses increased to $22.0 million from $16.0 million year-over-year, while general and administrative expenses rose to $12.8 million from $7.8 million. The company ended the quarter with $249.8 million in cash and cash equivalents, which it expects to fund operations into the second half of 2029.
Key takeaways
Net loss widened to $32.4 million in Q3 2026 from $20.3 million in Q3 2025, driven by increased R&D and G&A spending
R&D expenses increased 37.4% year-over-year to $22.0 million, reflecting development expenses, personnel costs, and restructuring-related costs
Cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029
Company plans to initiate AscenSION CF Phase 2 proof-of-concept trial for SION-451 + SION-2222 dual combination in Q1 2027
Workforce reduction of approximately 46% implemented in September 2026 to extend operating runway
Post hoc analyses of PreciSION CF trial showed mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta after excluding three participants with dosing non-adherence
Clinical and nonclinical data presented at 2026 North American Cystic Fibrosis Conference supporting advancement of NBD1 stabilizer combinations
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow SION in real time
Get material earnings, filing, IR, and earnings-call alerts by email.